Home
Safe Snack Guide
Allergence
#SnackSafelyAtHome
About Us
SnackSafely.com Media Kit
SnackSafely.com Consumer Brochure
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
SnackSafely.com
Home
Safe Snack Guide
Allergence
#SnackSafelyAtHome
About Us
SnackSafely.com Media Kit
SnackSafely.com Consumer Brochure
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Emerging Therapy
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Emerging Therapy
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
News Wire ~ 3rd Party Press Release
-
2020/05/28
Emerging Therapy
Allerdent Enables Patients to Maintain Seasonal Allergy Immunotherapy During COVID-19 Pandemic
News Wire ~ 3rd Party Press Release
-
2020/05/06
Emerging Therapy
Oral Immunotherapy: What You Should Know, and What’s New (Webinar)
Dave Bloom
-
2020/04/30
Emerging Therapy
Pending Litigation Shows Food Allergy Treatments in Development are Sometimes Overhyped
Dave Bloom
-
2020/04/24
Emerging Therapy
BlueWillow Completes Preclinical Studies of Intranasal Peanut Allergy Vaccine
Dave Bloom
-
2020/04/03
Emerging Therapy
FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...
Dave Bloom
-
2020/03/17
Emerging Therapy
ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI...
News Wire ~ 3rd Party Press Release
-
2020/03/02
Emerging Therapy
FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...
News Wire ~ 3rd Party Press Release
-
2020/02/22
Emerging Therapy
Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...
News Wire ~ 3rd Party Press Release
-
2020/02/21
Emerging Therapy
End Allergies Together Announces Winners of $1 Million Grand Challenge to...
News Wire ~ 3rd Party Press Release
-
2020/02/12
1
2
3
...
13
Page 1 of 13
